Pittsburgh Compound B
ApprovedSmall molecule
Pittsburgh Compound B is one of 16 small molecule programs targeting Alzheimer's Disease. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Alzheimer's Disease
#DrugCompanyPhaseTrials
1Kisunla
Eli LillyPhase 3
Leqembi
EisaiPhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Approved
Qalsody
BiogenPhase 3
Aduhelm
BiogenPhase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Karxt
Bristol-Myers SquibbPhase 3
F-18 FDG
SStanford University
Approved
Pittsburgh Compound B
MMayo Clinic
Approved
Avandia
Alnylam PharmaceuticalsPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pittsburgh Compound B. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMayo Clinic